This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Standalone Q2 FY27 revenue dips 1.2 percent; profit and EBITDA margin decline
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone Q2 revenue for the quarter ended 30 September 2026 was Rs 1,277.71 lakh, down 1.2 percent from Rs 1,292.63 lakh last year, while profit after tax was Rs 131.92 lakh versus Rs 140.36 lakh. EBITDA margin fell to 13.0 percent from 14.6 percent. Standalone half-year revenue was Rs 2,177.95 lakh, profit after tax Rs 114.11 lakh and operating cash flow was positive at Rs 390.32 lakh. Prior-period figures were regrouped or reclassified.
Quarterly revenue, profit and EBITDA margin fell, which may weigh on the stock, though positive half-year operating cash flow offers support.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹12.78 Cr | ₹12.93 Cr | −1.2% |
| Operating profit | ₹1.51 Cr | ₹1.73 Cr | −12.4% |
| Profit after tax | ₹1.32 Cr | ₹1.40 Cr | −6.0% |
| EBITDA margin | 13.0% | 14.6% | −1.6 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.